- Home
- RLYB vs SYBX Comparison
RLYB vs SYBX Comparison
Compare RLYB & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- SYBX
- Stock Information
- Founded
- RLYB 2018
- SYBX N/A
- Country
- RLYB United States
- SYBX United States
- Employees
- RLYB N/A
- SYBX N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- SYBX Health Care
- Exchange
- RLYB Nasdaq
- SYBX Nasdaq
- Market Cap
- RLYB 24.1M
- SYBX 20.0M
- IPO Year
- RLYB 2021
- SYBX N/A
- Fundamental
- Price
- RLYB $0.61
- SYBX $1.77
- Analyst Decision
- RLYB Hold
- SYBX
- Analyst Count
- RLYB 2
- SYBX 0
- Target Price
- RLYB N/A
- SYBX N/A
- AVG Volume (30 Days)
- RLYB 290.8K
- SYBX 35.5K
- Earning Date
- RLYB 11-07-2025
- SYBX 11-11-2025
- Dividend Yield
- RLYB N/A
- SYBX N/A
- EPS Growth
- RLYB N/A
- SYBX N/A
- EPS
- RLYB N/A
- SYBX N/A
- Revenue
- RLYB $761,000.00
- SYBX N/A
- Revenue This Year
- RLYB N/A
- SYBX N/A
- Revenue Next Year
- RLYB N/A
- SYBX N/A
- P/E Ratio
- RLYB N/A
- SYBX N/A
- Revenue Growth
- RLYB 154.51
- SYBX N/A
- 52 Week Low
- RLYB $0.22
- SYBX $0.90
- 52 Week High
- RLYB $1.24
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- RLYB 61.83
- SYBX 56.70
- Support Level
- RLYB $0.54
- SYBX $1.64
- Resistance Level
- RLYB $0.57
- SYBX $1.87
- Average True Range (ATR)
- RLYB 0.04
- SYBX 0.09
- MACD
- RLYB 0.01
- SYBX -0.00
- Stochastic Oscillator
- RLYB 93.92
- SYBX 64.91
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.